Certican

Everolimus (Certican; Novartis Pharma AG, Basel, Switzerland) represents the latest generation of proliferation signal inhibitors… (More)

BACKGROUND Everolimus is a proliferation signal-inhibitor recently introduced in heart transplant recipients. To date, little is… (More)

BACKGROUND/METHODS This observational study reports on immunosuppression with cyclosporine (CsA) in 38 de novo heart transplant… (More)

The calcineurin inhibitors (CNIs) have been the cornerstone of immunosuppressive therapy in recent years, though their… (More)

BACKGROUND Everolimus (Certican), a novel proliferation signal inhibitor, allows calcineurin inhibitor dose reduction in… (More)

The proliferation signal inhibitor everolimus is efficacious for reducing the incidence of acute rejection and cardiac allograft… (More)

The Certican Consensus Conference has produced guidelines to help physicians apply Certican (everolimus) clinical trial data in… (More)

Immunosuppressant agents have greatly increased graft and overall survival in heart transplant patients, but some of these agents… (More)

BACKGROUND With an increasing number of elderly patients now waiting for a kidney transplant, and the percentage of kidney donors… (More)

BACKGROUND Everolimus is a proliferation inhibitor designed to target chronic rejection, including prevention of acute rejection… (More)